Shares of Adaptimmune Therapeutics PLC (NASDAQ:ADAP) have been assigned a consensus recommendation of “Hold” from the eight brokerages that are presently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and three have given a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $15.50.

ADAP has been the topic of a number of recent analyst reports. Zacks Investment Research raised Adaptimmune Therapeutics PLC from a “hold” rating to a “buy” rating and set a $5.25 target price on the stock in a research report on Wednesday, July 12th. ValuEngine raised Adaptimmune Therapeutics PLC from a “strong sell” rating to a “sell” rating in a research report on Thursday, July 20th. BidaskClub raised Adaptimmune Therapeutics PLC from a “strong sell” rating to a “sell” rating in a research report on Saturday, July 8th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Adaptimmune Therapeutics PLC in a research report on Tuesday, June 6th.

Several large investors have recently bought and sold shares of the stock. Renaissance Technologies LLC raised its stake in Adaptimmune Therapeutics PLC by 35.4% in the fourth quarter. Renaissance Technologies LLC now owns 445,100 shares of the biotechnology company’s stock valued at $1,803,000 after buying an additional 116,400 shares in the last quarter. Creative Planning raised its stake in Adaptimmune Therapeutics PLC by 32.8% in the first quarter. Creative Planning now owns 40,500 shares of the biotechnology company’s stock valued at $223,000 after buying an additional 10,000 shares in the last quarter. Granite Investment Partners LLC purchased a new stake in Adaptimmune Therapeutics PLC during the first quarter valued at about $1,078,000. Essex Investment Management Co. LLC purchased a new stake in Adaptimmune Therapeutics PLC during the first quarter valued at about $225,000. Finally, Raymond James Financial Services Advisors Inc. purchased a new stake in Adaptimmune Therapeutics PLC during the first quarter valued at about $120,000. 56.34% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Adaptimmune Therapeutics PLC (ADAP) Given Average Recommendation of “Hold” by Analysts” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright law. The legal version of this article can be read at https://www.americanbankingnews.com/2017/08/18/adaptimmune-therapeutics-plc-adap-given-average-recommendation-of-hold-by-analysts.html.

Shares of Adaptimmune Therapeutics PLC (NASDAQ:ADAP) traded down 3.26% during mid-day trading on Friday, reaching $5.05. 172,564 shares of the company traded hands. Adaptimmune Therapeutics PLC has a 52-week low of $3.76 and a 52-week high of $8.36.

Adaptimmune Therapeutics PLC (NASDAQ:ADAP) last announced its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.24). Adaptimmune Therapeutics PLC had a negative return on equity of 38.73% and a negative net margin of 438.00%. The company had revenue of $3.52 million for the quarter, compared to analyst estimates of $5.43 million. Equities research analysts predict that Adaptimmune Therapeutics PLC will post ($1.05) earnings per share for the current fiscal year.

About Adaptimmune Therapeutics PLC

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.

Analyst Recommendations for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.